According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...read more
ProFactor Pharma Ltd (PFP) is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd...read more